Print this page
-
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Protocol: 001720Applicable Disease Sites: Liver
-
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Liver -
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.
Protocol: 072213Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver -
A Phase II, open-label, multi-cohort, multicenter study in patients with unresectable HEPATOCELLULAR CARCINOMA and CHILDPUGH B7 and B8 Cirrhosis
Protocol: 072309Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Liver -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Protocol: 072311Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver